Get the Stockscreener App
1.45
0.69%
0.01
After Hours:
1.45
Vivani Medical Inc stock is traded at $1.45, with a volume of 267.26K.
It is up +0.69% in the last 24 hours and up +15.08% over the past month.
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. It develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division.
See More
Previous Close:
$1.44
Open:
$1.44
24h Volume:
267.26K
Relative Volume:
2.64
Market Cap:
$85.30M
Revenue:
-
Net Income/Loss:
$-25.65M
P/E Ratio:
-3.7179
EPS:
-0.39
Net Cash Flow:
$-24.59M
1W Performance:
+12.40%
1M Performance:
+15.08%
6M Performance:
-13.17%
1Y Performance:
+52.63%
1-Day Range:
$1.44
$1.50
1-Week Range:
$1.29
$1.50
52-Week Range:
$0.84
$7.80
Vivani Medical Inc Stock (VANI) Company Profile
Name
Vivani Medical Inc
Sector
Industry
Phone
818-833-5000
Address
1350 S. LOOP ROAD, ALAMEDA
Compare VANI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VANI
Vivani Medical Inc
|
1.45 | 85.30M | 0 | -25.65M | -24.59M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Vivani Medical Inc Stock (VANI) Latest News
Financial Review: Vivani Medical (NASDAQ:VANI) vs. Heyu Biological Technology (OTCMKTS:HYBT) - Defense World
Independent Chairman of the Board of Vivani Medical Gregg Williams Buys 30% More Shares - Simply Wall St
Vivani Medical: Q3 Earnings Snapshot - Darien Times
Vivani Medical Reports Q3 Loss, Advances GLP-1 Trials - TipRanks
Vivani Medical, Inc. (NASDAQ:VANI) Director Gregg Williams Purchases 3,968,253 Shares - MarketBeat
Vivani medical director Gregg Williams buys $5 million in stock By Investing.com - Investing.com Nigeria
Vivani medical director Gregg Williams buys $5 million in stock - Investing.com India
Vivani Medical Secures Funding for GLP-1 Implant Trial - TipRanks
Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results - Business Wire
Vivani Medical (NASDAQ:VANI) Now Covered by HC Wainwright - Defense World
HC Wainwright & Co. Initiates Coverage of Vivani Medical (VANI) with Buy Recommendation - MSN
3 US Penny Stocks To Monitor In October 2024 - Simply Wall St
Vivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024 - Business Wire
Vivani Medical's Market Cap Up US$6.6m Following Year Of Insider Stock Buying - Simply Wall St
Vivani Medical (NASDAQ:VANI) Shares Up 0.9%Here's Why - MarketBeat
Vivani Medical's chief business officer buys shares worth $2,835 - Investing.com India
Vivani Medical's chief business officer buys shares worth $2,835 By Investing.com - Investing.com Australia
Thursday's Insider Trading Moves: Top Buys and Sells in US Stocks - Investing.com India
Precision Optics (OTCMKTS:PEYE) & Vivani Medical (NASDAQ:VANI) Head-To-Head Analysis - Defense World
Vivani Medical (NASDAQ:VANI) Stock Quotes, Forecast and News Summary - Benzinga
Vivani Medical obtains Australian approval to begin GLP-1 implant trial - Yahoo Finance
Vivani Medical's implant trial gets Australian regulatory nod - Investing.com Australia
Vivani Medical's implant trial gets Australian regulatory nod By Investing.com - Investing.com Canada
Vivani Medical to Test Implant in Obese and Overweight Patients - Yahoo Finance
Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia - Business Wire
EXCLUSIVE: Vivani Medical Advances Its Obesity Treatment Implant With New Clinical Trial in Australia - Yahoo Finance
Ventyx deal a sign of Sanofi’s growing interest neuro-immunology? - BioCentury
Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m deal - Yahoo! Voices
Ventyx stock climbs 8% on $27M Sanofi investment - MSN
Sanofi scoops negotiation rights to Ventyx obesity, Parkinson's candidate for $27M - Fierce Biotech
Vicebio secures $100m to advance RSV and hMPV vaccine combo to Phase I - Pharmaceutical Technology
Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024 - Business Wire
Ventyx Biosciences Shares Rise Premarket on Sanofi Investment - Marketscreener.com
Commonwealth Equity Services LLC Has $416,000 Stock Position in Vivani Medical, Inc. (NASDAQ:VANI) - Defense World
Viva Leisure Continues Share Buy-Back Initiative - TipRanks
First Eagle Investment Management LLC Purchases New Holdings in Silvaco Group, Inc. (NASDAQ:SVCO) - MarketBeat
Form 425 Revelyst, Inc. Filed by: Vista Outdoor Inc. - StreetInsider.com
Vista Outdoor Board of Directors Sends Letter to Stockholders Highlighting Reasons to Vote FOR Value Maximizing CSG Transaction - Yahoo Finance
Viva Leisure Continues Share Buy-Back Effort - TipRanks
Vista Outdoor considering sale of Revelyst, urges transaction with CSG - MSN
Vista Outdoor considering sale of Revelyst, urges transaction with CSG (VSTO) - Seeking Alpha
Vivani Medical (NASDAQ:VANI) Shares Down 2.3% - MarketBeat
Vivani Medical (NASDAQ:VANI) Trading Down 2.3% - Defense World
EXCLUSIVE: Vivani Medical Reveals Positive Preclinical Liver Fat Results From Miniature GLP-1 Implant For Obesity - MSN
Stock Performance Spotlight: Vivani Medical Inc (VANI) Ends the Day at 1.21, Down by -1.63 - The Dwinnex
Vivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting GLP-1 Implant - Morningstar
Vivani Medical Inc Stock (VANI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):